ngd-4715 ngd-4715 ngd-4715 is a drug developed by neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor mch1. in animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed phase i clinical trials in humans. ngd-4715identifierscas number873318-96-8chemical and physical dataformulac25h30f3n3o3molar mass477.528 g·mol−13d model (jsmol)interactive image smiles 12ccc(n1ccn(c2)c(=o)c1=cc=c(n=c1)c(f)(f)f)c1=cc=c(occo)c(c)=c1c neurogen was acquired by ligand pharmaceuticals in august, 2009, and ngd-4715 was not listed among its key assets. all four laboratories were closed and sold, and no employees were retained. the structure of ngd-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.